Ben van der Schaaf

Partner

Areas of Focus

Education

Henley Management College
Business Design; Business & Enterprise Architecture
University of Maine - School of Business
Master of Business Administration
NIVRA-Nyenrode
NACII, Accountancy

Past Experience

PA Consulting Group
Management Consultant
The Tussauds Group
Director of Finance
Ernst & Young
Auditor

Ben is a Partner at Arthur D. Little based in Boston. He is an experienced management consultant and program manager with an international background in finance and general management.

He is focused on the life sciences and healthcare sector, specifically working in pharmaceutical R&D and commercial operations.

Experience includes post-merger integration, complex program delivery, quality & compliance, strategic sourcing & partnering, organizational analysis and design, commercialization, sales-force effectiveness and operations management.

He is skilled in stakeholder management, change management and collaboration, and has strong analytical and financial management skills and broad international business experience. He operates comfortably at senior levels.

Ben holds an MBA with an operations and finance concentration, and an undergraduate degree in accounting and auditing.

He is fluent in Dutch and English.

Recent Publications

The pandemic stress test
Ben van der Schaaf, Florent Nansé
There’s an old joke that we may have all heard at one time or another: “My doctor asked me if I had ever had a stress test. Sure … it’s called life!” Today, and for some time to come, the COVID-19 pandemic has become part of our daily lives and is providing the biggest stress test of our lifetime.
Find out more
The ecosystem future
Shinichi Akayama, Dr. Raymond Khoury, Ben van der Schaaf
Find out more
Hyper-collaboration in the healthcare and life science industry – The new imperative
Dr. Franziska Thomas, Ben van der Schaaf, Dr. Ulrica Sehlstedt
The COVID-19 pandemic demonstrated the ability of the healthcare and life science industry to respond to unexpected needs with unprecedented speed. However, independent of the pandemic, the industry was already facing transformation in light of multiple, highly disruptive innovations not only in the traditional field of drug modalities but also in related fields such as digital, AI, data, and medical devices.
Find out more
Pharma: Strategic realignment for a better future
Ben van der Schaaf
Amid the search for effective COVID-19 treatments and vaccines, the pandemic will have long-term side effects for the global pharmaceutical industry. As our article explains, companies will need to focus on change in three areas (portfolio reprioritization, accelerated R&D and technology transformation) if they are to position themselves successfully for the future.
Find out more
The Company of Tomorrow
Shinichi Akayama, Ralf Baron, Rick Eagar, Dr. Raymond Khoury, Michael Kolk, Thomas Kuruvilla, Francesco Marsella, Greg Smith, Ben van der Schaaf
The COVID-19 crisis hit the world as this edition of Prism was in preparation. Needless to say, the outlook for business, at least in the short term, has changed radically in just a few weeks. Nevertheless, it’s becoming increasingly clear that one effect of the crisis has been acceleration of trends that were already there, such as virtualization of the workplace, further penetration of digital technologies (for example, AI and the IoT), and “asset-light” business models that make businesses more responsive and resilient to rapid shocks.
Find out more

Ben is a Partner at Arthur D. Little based in Boston. He is an experienced management consultant and program manager with an international background in finance and general management.

He is focused on the life sciences and healthcare sector, specifically working in pharmaceutical R&D and commercial operations.

Experience includes post-merger integration, complex program delivery, quality & compliance, strategic sourcing & partnering, organizational analysis and design, commercialization, sales-force effectiveness and operations management.

He is skilled in stakeholder management, change management and collaboration, and has strong analytical and financial management skills and broad international business experience. He operates comfortably at senior levels.

Ben holds an MBA with an operations and finance concentration, and an undergraduate degree in accounting and auditing.

He is fluent in Dutch and English.

Recent Publications

The pandemic stress test
Ben van der Schaaf, Florent Nansé
There’s an old joke that we may have all heard at one time or another: “My doctor asked me if I had ever had a stress test. Sure … it’s called life!” Today, and for some time to come, the COVID-19 pandemic has become part of our daily lives and is providing the biggest stress test of our lifetime.
Find out more
The ecosystem future
Shinichi Akayama, Dr. Raymond Khoury, Ben van der Schaaf
Find out more
Hyper-collaboration in the healthcare and life science industry – The new imperative
Dr. Franziska Thomas, Ben van der Schaaf, Dr. Ulrica Sehlstedt
The COVID-19 pandemic demonstrated the ability of the healthcare and life science industry to respond to unexpected needs with unprecedented speed. However, independent of the pandemic, the industry was already facing transformation in light of multiple, highly disruptive innovations not only in the traditional field of drug modalities but also in related fields such as digital, AI, data, and medical devices.
Find out more
Pharma: Strategic realignment for a better future
Ben van der Schaaf
Amid the search for effective COVID-19 treatments and vaccines, the pandemic will have long-term side effects for the global pharmaceutical industry. As our article explains, companies will need to focus on change in three areas (portfolio reprioritization, accelerated R&D and technology transformation) if they are to position themselves successfully for the future.
Find out more
The Company of Tomorrow
Shinichi Akayama, Ralf Baron, Rick Eagar, Dr. Raymond Khoury, Michael Kolk, Thomas Kuruvilla, Francesco Marsella, Greg Smith, Ben van der Schaaf
The COVID-19 crisis hit the world as this edition of Prism was in preparation. Needless to say, the outlook for business, at least in the short term, has changed radically in just a few weeks. Nevertheless, it’s becoming increasingly clear that one effect of the crisis has been acceleration of trends that were already there, such as virtualization of the workplace, further penetration of digital technologies (for example, AI and the IoT), and “asset-light” business models that make businesses more responsive and resilient to rapid shocks.
Find out more

More About Ben
  • Henley Management College
    Business Design; Business & Enterprise Architecture
  • University of Maine - School of Business
    Master of Business Administration
  • NIVRA-Nyenrode
    NACII, Accountancy
  • PA Consulting Group
    Management Consultant
  • The Tussauds Group
    Director of Finance
  • Ernst & Young
    Auditor